129 related articles for article (PubMed ID: 38531691)
1. Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
Sander N; Stölzl D; Fonfara M; Hartmann J; Harder I; Suhrkamp I; Jakaša I; van den Bogaard E; van Vlijmen-Willems I; Szymczak S; Rodriguez E; Gerdes S; Weidinger S
Br J Dermatol; 2024 Mar; ():. PubMed ID: 38531691
[TBL] [Abstract][Full Text] [Related]
2. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
[TBL] [Abstract][Full Text] [Related]
3. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
Beck LA; Bieber T; Weidinger S; Tauber M; Saeki H; Irvine AD; Eichenfield LF; Werfel T; Arlert P; Jiang L; Røpke M; Paller AS
J Am Acad Dermatol; 2023 Apr; 88(4):816-823. PubMed ID: 36473633
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolidone carboxylic acid levels or caspase-14 expression in the corneocytes of lesional skin correlates with clinical severity, skin barrier function and lesional inflammation in atopic dermatitis.
Jung M; Choi J; Lee SA; Kim H; Hwang J; Choi EH
J Dermatol Sci; 2014 Dec; 76(3):231-9. PubMed ID: 25315296
[TBL] [Abstract][Full Text] [Related]
5. Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis.
Stolarczyk A; Perez-Nazario N; Knowlden SA; Chinchilli E; Grier A; Paller A; Gill SR; De Benedetto A; Yoshida T; Beck LA
Arch Dermatol Res; 2023 Dec; 315(10):2883-2892. PubMed ID: 37755506
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis.
Berdyshev E; Goleva E; Bissonnette R; Bronova I; Bronoff AS; Richers BN; Garcia S; Ramirez-Gama M; Taylor P; Praestgaard A; Agueusop I; Jurvilliers P; Boguniewicz M; Levit NA; Rossi AB; Zhang A; Leung DYM
Allergy; 2022 Nov; 77(11):3388-3397. PubMed ID: 35815904
[TBL] [Abstract][Full Text] [Related]
7. Correlation between serum thymus and activation-regulated chemokine levels and stratum corneum barrier function in healthy individuals and patients with mild atopic dermatitis.
Furue M; Matsumoto T; Yamamoto T; Takeuchi S; Esaki H; Chiba T; Yamaguchi H
J Dermatol Sci; 2012 Apr; 66(1):60-3. PubMed ID: 22391243
[TBL] [Abstract][Full Text] [Related]
8. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab Therapy Improves Stratum Corneum Hydration and Skin Dysbiosis in Patients With Atopic Dermatitis.
Lee SJ; Kim SE; Shin KO; Park K; Lee SE
Allergy Asthma Immunol Res; 2021 Sep; 13(5):762-775. PubMed ID: 34486260
[TBL] [Abstract][Full Text] [Related]
10. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
Simpson EL; Guttman-Yassky E; Eichenfield LF; Boguniewicz M; Bieber T; Schneider S; Guana A; Silverberg JI
Allergy; 2023 Nov; 78(11):2875-2891. PubMed ID: 37455359
[TBL] [Abstract][Full Text] [Related]
11. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis.
Danby SG; Andrew PV; Taylor RN; Kay LJ; Chittock J; Pinnock A; Ulhaq I; Fasth A; Carlander K; Holm T; Cork MJ
Clin Exp Dermatol; 2022 Jun; 47(6):1154-1164. PubMed ID: 35167133
[TBL] [Abstract][Full Text] [Related]
12. Skin Barrier Function in Psoriasis and Atopic Dermatitis: Transepidermal Water Loss and Temperature as Useful Tools to Assess Disease Severity.
Montero-Vilchez T; Segura-Fernández-Nogueras MV; Pérez-Rodríguez I; Soler-Gongora M; Martinez-Lopez A; Fernández-González A; Molina-Leyva A; Arias-Santiago S
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33477944
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
[TBL] [Abstract][Full Text] [Related]
14. Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis.
Guttman-Yassky E; Diaz A; Pavel AB; Fernandes M; Lefferdink R; Erickson T; Canter T; Rangel S; Peng X; Li R; Estrada Y; Xu H; Krueger JG; Paller AS
JAMA Dermatol; 2019 Dec; 155(12):1358-1370. PubMed ID: 31596431
[TBL] [Abstract][Full Text] [Related]
15. Barrier function and natural moisturizing factor levels after cumulative exposure to a fruit-derived organic acid and a detergent: different outcomes in atopic and healthy skin and relevance for occupational contact dermatitis in the food industry.
Angelova-Fischer I; Hoek AK; Dapic I; Jakasa I; Kezic S; Fischer TW; Zillikens D
Contact Dermatitis; 2015 Dec; 73(6):358-63. PubMed ID: 26426984
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Food Sensitization in Children with Atopic Dermatitis Based on Disease Severity and Epidermal Layer Impairment.
Tran NLH; Ly NTM; Trinh HKT; Le MK; Vo NVT; Pham DL
Int Arch Allergy Immunol; 2024; 185(1):43-55. PubMed ID: 37899044
[TBL] [Abstract][Full Text] [Related]
17. Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations.
Horimukai K; Morita K; Narita M; Kondo M; Kabashima S; Inoue E; Sasaki T; Niizeki H; Saito H; Matsumoto K; Ohya Y
Allergol Int; 2016 Jan; 65(1):103-8. PubMed ID: 26666481
[TBL] [Abstract][Full Text] [Related]
18. Children with atopic dermatitis show increased activity of β-glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu.
Kezic S; McAleer MA; Jakasa I; Goorden SMI; der Vlugt KG; Beers-Stet FS; Meijer J; Roelofsen J; Nieman MM; van Kuilenburg ABP; Irvine AD
Br J Dermatol; 2022 Jun; 186(6):988-996. PubMed ID: 34993951
[TBL] [Abstract][Full Text] [Related]
19. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
20. The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update.
Çetinarslan T; Kümper L; Fölster-Holst R
Front Mol Biosci; 2023; 10():1159404. PubMed ID: 37654796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
